Hormonal
12 weeks of 500 mg/day Sensoril supplementation favors body mass distribution by reducing the increase in the android/gynoid ratio compared to placebo, without significantly altering total body fat or lean mass.
If you are looking to optimize body composition, 500 mg/day of Sensoril may help you maintain a healthier fat distribution (lower android/gynoid ratio) compared to placebo, even if it doesn't directly cause fat loss or muscle gain. This is a subtle benefit that supports long-term metabolic health.
Changes in DEXA-derived android/gynoid ratio (S500: +0.0 ± 0.14 vs. PLA: +0.09 ± 0.1, p = 0.03) also favored S500... No other statistically significant outcomes were noted for body mass or body composition variables
Why this rating
Statistically significant between-group difference in a secondary outcome (android/gynoid ratio) in a well-controlled trial.
Source
Effects of an Aqueous Extract of Withania somnifera on Strength Training Adaptations and Recovery: The STAR Trial
Tim N. Ziegenfuss et al. · Nutrients · 2018
DOI 10.3390/nu10111807
More from this paper
- Supplementation with 500 mg/day of Sensoril (aqueous ashwagandha extract) for 12 weeks significantly increases maximal strength (1-RM squat and bench press) and aerobic endurance (7.5 km cycling time trial) in recreationally active men undergoing resistance training compared to placebo.Good
- 12 weeks of 500 mg/day Sensoril supplementation improves perceived recovery scores and prevents the increase in perceived soreness seen with placebo in recreationally active men.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →